Predictors of growth patterns in children with mucopolysaccharidosis I after haematopoietic stem cell transplantation.
Stefanie MaierMiroslav ZivicnjakLorenz GrigullJulia B HennermannCharlotte AriesBritta Maecker-KolhoffMartin SauerAnibh M DasRita BeierPublished in: JIMD reports (2022)
Mucopolysaccharidosis type I (MPS I) is an autosomal-recessive metabolic disorder caused by an enzyme deficiency of lysosomal alpha-l-iduronidase (IDUA). Haematopoietic stem cell transplantation (HSCT) is the therapeutic option of choice in MPS I patients younger than 2.5 years, which has a positive impact on neurocognitive development. However, impaired growth remains a problem. In this monocentric study, 14 patients with MPS I (mean age 1.72 years, range 0.81-3.08) were monitored according to a standardised follow-up program after successful allogeneic HSCT. A detailed anthropometric program was carried out to identify growth patterns and to determine predictors of growth in these children. All patients are alive and in outpatient care (mean follow-up 8.1 years, range 0.1-16.0). Progressively lower standard deviation scores (SDS) were observed for body length (mean SDS -1.61; -4.58 - 3.29), weight (-0.56; -3.19 - 2.95), sitting height (-3.28; -7.37 - 0.26), leg length (-1.64; -3.88 - 1.49) and head circumference (0.91; -2.52 - 6.09). Already at the age of 24 months, significant disproportions were detected being associated with increasing deterioration in growth for age. Younger age at HSCT, lower counts for haemoglobin and platelets, lower potassium, higher donor-derived chimerism, higher counts for leukocytes and recruitment of a matched unrelated donor (MUD) positively correlated with body length ( p ≤ 0.05). In conclusion, this study characterised predictors and aspects of growth patterns in children with MPS I after HSCT, underlining that early HSCT of MUD is essential for slowing body disproportion.
Keyphrases
- stem cell transplantation
- high dose
- body mass index
- end stage renal disease
- hematopoietic stem cell
- young adults
- newly diagnosed
- ejection fraction
- healthcare
- chronic kidney disease
- prognostic factors
- bone marrow
- weight loss
- low dose
- palliative care
- acute myeloid leukemia
- body composition
- intellectual disability
- autism spectrum disorder
- replacement therapy
- patient reported outcomes
- allogeneic hematopoietic stem cell transplantation
- affordable care act
- duchenne muscular dystrophy
- muscular dystrophy